Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Moberg Derma AB

This article was originally published in Start Up

Executive Summary

Swedish dermatology specialty pharma Moberg Derma AB is using its Kaprolac platform to build a portfolio of non-steroidal, topical treatments that it thinks will have improved therapeutic outcomes and mitigated side-effect profiles. Kaprolac is a combination of several well-known, safe dermatological compounds that have given rise to a potential 10 new treatments in Moberg Derma's pipeline.

You may also be interested in...



Start-Up Previews (10/2007)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Cardiovascular Drug Start-Ups," features profiles of AcelleRX Therapeutics, BioVascular, Nile Therapeutics and VIA Pharmaceuticals. Plus these Start-Ups Across Health Care: JenaValve, Moberg Derma, ProtAffin, and Virtual Ports.

Start-Up Previews (10/2007)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Cardiovascular Drug Start-Ups," features profiles of AcelleRX Therapeutics, BioVascular, Nile Therapeutics and VIA Pharmaceuticals. Plus these Start-Ups Across Health Care: JenaValve, Moberg Derma, ProtAffin, and Virtual Ports.

Chester Valley Pharmaceuticals Inc.

In a year that saw a number of significant private financings in dermatology, Chester Valley Pharmaceuticals Inc. was one of the standouts. The specialty pharma was formed in November 2004 by dermatology industry veterans Robert J. Moccia and Xavier Yon, and by private equity firm GTCR Golder Rauner LLC, which has made a $75 million equity commitment to the new company.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel